Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 9, 2013WATCHMAN® Device Continues to Demonstrate Positive Clinical Outcomes for Patients with Atrial Fibrillation
Boston Scientific Corporation (NYSE: BSX) announces the preliminary analysis of the PREVAIL clinical trial data is now available on TCTMD at...
-
Mar 9, 2013
Boston Scientific Corporation (NYSE: BSX) reports preliminary data in the PREVAIL clinical trial met two out of three co-primary endpoints. The...
-
Mar 6, 2013First Presentation of the Preliminary Results of All Three Co-Primary Endpoints to be Revealed During The American College of Cardiology 2013 Annual Scientific Sessions
The Boston Scientific Corporation (NYSE: BSX) PREVAIL clinical trial results will be presented in a Late-Breaking Clinical Trial presentation at the...
-
Mar 6, 2013New Tool Available to Assist in the Treatment of Peripheral Arterial Disease
Boston Scientific Corporation (NYSE: BSX) has begun the launch of its 0.035" and 0.018" Rubicon™ Support Catheter in the United States. The device...
-
Mar 4, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to present sponsored research at the 62nd Annual Scientific Session of the American College of...
-
Feb 21, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2013 RBC Capital Markets Healthcare Conference on February 26 in New...
-
Feb 20, 2013
(Feb. 20, 2013 US Time) Boston Scientific Corporation (NYSE: BSX) subsidiary Boston Scientific Japan K.K. has reached an agreement with Fukuda Denshi Co., Ltd. to market and sell the Boston...
-
Feb 20, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Citi 2013 Global Healthcare Conference on February 25 in New York....
-
Feb 12, 2013The Next Advance in Durable Polymer Stent Technology from Boston Scientific is Now Available in Europe and Other Select Geographies
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent...
-
Feb 6, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2013 Leerink Swann Global Healthcare Conference on February 13 in New York....
-
Jan 29, 2013Organizations Team up to Raise awareness and Make a Call to Action for European Governments to Develop Comprehensive Chronic Pain Treatment Programs
Paris (January 29, 2013) – Boston Scientific Corporation (NYSE:BSX) today released results of a survey of more than 1,000 chronic pain sufferers across Europe that suggest millions of...
-
Jan 29, 2013
Boston Scientific Corporation (NYSE: BSX) announces financial results for the fourth quarter and full year ended December 31, 2012, as well as sales...
-
Jan 17, 2013
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the fourth quarter and full year ended...
-
Jan 16, 2013
The first patient has been treated in the Boston Scientific Corporation (NYSE: BSX) ZERO AF clinical trial to evaluate the safety and effectiveness of...
-
Jan 8, 2013
Boston Scientific Corporation (NYSE: BSX) will host an Investor Day meeting on Tuesday, February 12, 2013. The meeting is scheduled to begin with a...
-
Dec 20, 2012
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 31st Annual J.P. Morgan Healthcare Conference in San Francisco on...
-
Dec 17, 2012Company Begins Evaluation of its Next Generation Pacing Leads
The first patient has been implanted with the Boston Scientific Corporation (NYSE: BSX) next generation INGEVITY™ pacing leads in a clinical trial...
-
Dec 12, 2012Close the Gap Initiative Urges Fans to Learn Their Risk Factors for Heart Disease and Take Responsibility for Their Heart Health
The Boston Scientific Corporation (NYSE: BSX) health equity initiative, Close the Gap, will once again be the title sponsor of the Crossroads Classic,...
-
Dec 7, 2012World's First and Only System with 32 Contacts and 32 Dedicated Power Sources is Designed to Provide Pain Relief to a Broad Spectrum of Chronic Pain Patients
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval and has begun the European market launch of the Precision Spectra™ Spinal...
-
Dec 4, 2012Study to Compare Clinical Outcomes of Self-Expanding Metal Stents (SEMS) Versus Plastic Stents for the Treatment of Biliary Strictures Caused by Chronic Pancreatitis
The first patient has been enrolled in a Boston Scientific Corporation (NYSE: BSX) study comparing the WallFlex® Biliary RX Fully Covered...
-
Nov 30, 2012
The first patient has been enrolled in the Boston Scientific Corporation (NYSE: BSX) EVOLVE II clinical trial, which is designed to further assess the...
-
Nov 20, 2012Devices Projected to Have up to Twice the Longevity of Comparable Products
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for increased longevity projections for the INCEPTA™, ENERGEN™, PUNCTUA™,...
-
Nov 8, 2012Company to Consolidate Natick, Mass. Headquarters into Existing Marlborough Site; Facility Expansion to Create Collaborative Campus Setting; Consolidation Expected to be Completed by Mid-Summer 2014
Natick, Mass. (November 8, 2012) – Boston Scientific Corporation (NYSE:BSX) announces it will consolidate its Natick, Mass. global headquarters into its Marlborough, Mass. location, where a new...
-
Nov 8, 2012Company to Strengthen Hypertension Program with Acquisition of Renal Denervation Technology
Boston Scientific Corporation (NYSE: BSX) is extending its reach into the strategically critical renal denervation market by signing a definitive...
-
Nov 6, 2012MADIT-RIT Clinical Trial Study Results Published Today in the New England Journal of Medicine
Boston Scientific Corporation (NYSE: BSX) and the University of Rochester Medical Center presented positive results from the Multicenter Automatic...